Share on StockTwits

Amicus Therapeutics (NASDAQ:FOLD) COO Bradley L. Campbell unloaded 7,000 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $6.00, for a total transaction of $42,000.00. Following the sale, the chief operating officer now directly owns 200,000 shares in the company, valued at approximately $1,200,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Amicus Therapeutics (NASDAQ:FOLD) traded up 3.16% during mid-day trading on Tuesday, hitting $6.20. 2,700,872 shares of the company’s stock traded hands. Amicus Therapeutics has a 52 week low of $1.77 and a 52 week high of $6.28. The stock has a 50-day moving average of $4.35 and a 200-day moving average of $2.93. The company’s market cap is $487.9 million.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.08. On average, analysts predict that Amicus Therapeutics will post $-0.94 earnings per share for the current fiscal year.

FOLD has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Amicus Therapeutics to $14.00 in a research note on Wednesday, August 20th. Separately, analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Finally, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.